Last reviewed · How we verify
Conditioning regimen
This conditioning regimen involves a combination of chemotherapy and radiation therapy to prepare the body for a bone marrow transplant.
This conditioning regimen involves a combination of chemotherapy and radiation therapy to prepare the body for a bone marrow transplant. Used for Preparation for bone marrow transplant in patients with hematological malignancies.
At a glance
| Generic name | Conditioning regimen |
|---|---|
| Also known as | Endoxan, Antithymocyte globulin (ATG) rabbit : Thymoglobulin, Antithymocyte globulin (ATG) horse : Atgam, nonmyeloablative preparative regimen |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The regimen typically includes high-dose chemotherapy and total body irradiation to eliminate cancer cells and suppress the immune system, making it possible for the new bone marrow to engraft and produce healthy blood cells.
Approved indications
- Preparation for bone marrow transplant in patients with hematological malignancies
Common side effects
- Nausea and vomiting
- Fatigue
- Hair loss
- Diarrhea
- Infection
Key clinical trials
- Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
- Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1, PHASE2)
- Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation (NA)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conditioning regimen CI brief — competitive landscape report
- Conditioning regimen updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI